MARKET OVERVIEW

The India peptide synthesis market size reached USD 30.86 Million in 2025 and is projected to grow to USD 52.48 Million by 2034, at a CAGR of 6.08% during the forecast period of 2026-2034. Driven by government support through the Production-Linked Incentive scheme, the expansion of CRDMO capabilities, and rising demand for complex peptide therapeutics like GLP-1 receptor agonists, the market reflects expanding opportunities and strengthening infrastructure. the report offers a comprehensive analysis of the industry, including India peptide synthesis market growth, share, and regional insights.

STUDY ASSUMPTION YEARS

• Base Year: 2025
• Historical Year/Period: 2020-2025
• Forecast Year/Period: 2026-2034

INDIA PEPTIDE SYNTHESIS MARKET KEY TAKEAWAYS

• Current Market Size: USD 30.86 Million as of 2025
• CAGR: 6.08% (2026-2034)
• Forecast Period: 2026-2034
• Government support via India’s Production-Linked Incentive (PLI) scheme reduces import dependence and promotes domestic API manufacturing.
• Rapid expansion of CRDMO capabilities with advanced peptide synthesis infrastructure and state-of-the-art facilities.
• Surging global demand for peptide therapeutics, such as GLP-1 receptor agonists for diabetes and obesity, boosts market opportunities.
• Challenges include complex regulatory compliance, stringent quality control requirements, and persistent import reliance for raw materials.
• Shortage of specialized skilled workforce and technical expertise gaps impact industry growth.

RECENT DEVELOPMENTS & NEWS

In October 2025, PolyPeptide Group announced a major capacity expansion at its Ambernath facility in India, enhancing its size and diversification. This expansion is part of PolyPeptide's strategic growth to strengthen its global peptide manufacturing network in response to rising demand for peptide-based therapeutics. Ambernath functions as one of PolyPeptide’s six globally GMP-certified sites, serving pharmaceutical, cosmetics, and theragnostic sectors.

Sample Request Link: https://www.imarcgroup.com/india-peptide-synthesis-market/requestsample

MARKET TRENDS

Government support is a key trend shaping the India peptide synthesis market. The Production-Linked Incentive (PLI) scheme, part of a broader INR 15,000 crore program, offers performance-linked financial incentives targeting critical bulk drugs and APIs. By March 2025, 38 essential APIs have been domestically produced, covering approximately 67% of previously imported APIs. Complementary infrastructure developments like bulk drug parks and raised foreign direct investment limits further create a conducive environment for growth. These initiatives reduce barriers to entry and promote innovation in peptide synthesis technologies.

The rapid expansion of Contract Research, Development, and Manufacturing Organization (CRDMO) capabilities is progressing in India’s pharmaceutical sector. Leading firms are investing in advanced peptide research and manufacturing centers, incorporating automation, robotics, and high-throughput platforms. In 2025, Sai Life Sciences launched a dedicated Peptide Research Center in Hyderabad and broke ground on a 100,000-square-foot Process R&D Center. These investments support peptides’ appeal in oncology, metabolic, cardiovascular, and infectious diseases due to their specificity and reduced off-target effects.

The global surge in peptide-based therapeutics represents a critical trend fueling India’s market. Peptides have diverse biological activities, and blockbuster GLP-1 receptor agonists like semaglutide and tirzepatide drive demand for manufacturing capabilities. Strategic acquisitions, such as Granules India’s purchase of Switzerland-based Senn Chemicals AG in April 2025, enhance expertise and international reach. With over 80 approved peptide therapeutics globally and more than 630 ongoing clinical trials since 2015, India’s cost advantage and skilled workforce position it to capture significant market share.

MARKET GROWTH FACTORS

India’s government-led Production-Linked Incentive (PLI) scheme is a major growth driver, initially allocating INR 6,940 crore (USD 850 million) for key bulk drugs, including APIs and intermediates. By incentivizing incremental domestic sales over six years, the program tackles import dependence especially on China. By supporting infrastructure development and raising foreign investment limits, the scheme enables financial backing for capital-intensive setups, advanced equipment, and quality systems, accelerating peptide synthesis market growth, particularly for anti-diabetic and anti-obesity therapeutics.

Another primary growth factor is the rapid expansion of CRDMO and CDMO capabilities with cutting-edge peptide synthesis infrastructure. Investments made in 2025 by Sai Life Sciences—such as a Peptide Research Center in Hyderabad and a new CMC Process R&D Center—highlight this trend. These developments boost process efficiency, scalability, and capabilities in peptide synthesis, appealing to oncology, metabolic, cardiovascular, and infectious disease markets due to high specificity and safety profiles, enhancing India’s competitive position in global pharmaceutical manufacturing.

Surging global demand for peptide therapeutics acts as a significant market growth factor. Peptides’ versatility as antimicrobial, antitumor, and hormonal agents makes them attractive. The diabetes and obesity segment, with treatments like GLP-1 receptor agonists, fuels demand for peptide manufacturing. Strategic acquisitions, for example, Granules India’s 2025 acquisition of Senn Chemicals AG for CHF 20 million, grant access to international expertise. With increasing clinical trials and approvals worldwide, India’s technical expertise and expanding CRDMO infrastructure provide considerable growth prospects.

Explore the Full Report with Charts, Table of Contents, and List of Figures: https://www.imarcgroup.com/india-peptide-synthesis-market

MARKET SEGMENTATION

Analysis by Product:

• Reagents and Consumables
  • Resins
  • Amino Acids
  • Coupling Reagents
  • Dyes and Fluorescent Labeling Reagents
  • Others
• Equipment
  • Peptide Synthesizers
  • Chromatography Equipment
  • Lyophilizers
  • Others
• Service

Analysis by Technology:

• Liquid Phase Peptide Synthesis (LPPS)
• Solid Phase Peptide Synthesis (SPPS)
• Hybrid Technology

Analysis by Application:

• Therapeutics
  • Cancer
  • Metabolic
  • Cardiovascular Disorder
  • Infectious Diseases
  • CNS
  • Gastrointestinal Disorders (GIT)
  • Pain
  • Respiratory
  • Dermatology
  • Renal Disorders
  • Others
• Research
• Diagnosis

Analysis by End Use:

• Pharmaceutical and Biotechnology Companies
• CDMOs and CROs
• Academic and Research Institutes

Analysis by Region:

• North India
• South India
• East India
• West India

REGIONAL INSIGHTS

The report segments the India peptide synthesis market into North India, South India, East India, and West India. Specific market share or CAGR values per region are not explicitly provided in the source, thus a dominant region cannot be conclusively identified. However, the market coverage indicates significant activity and growth potential across all these regions.

Discuss Your Needs with Our Analyst – Get Customized Report Now

KEY PLAYERS

• Sai Life Sciences
• Granules India
• PolyPeptide Group

Customization Note:

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

ABOUT US

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

CONTACT US

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302